Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMUXMVQ)

Drug Name

Tyr-D-Ala-Gly-Trp-Nle-Asp-Phe-NH2 Drug Info

Synonyms

Tyr-D-Ala-Gly-Trp-Nle-Asp-Phe-NH2; CCK-Opioid Peptide, 8; CHEMBL262172; BDBM21138; (3S)-3-[(2S)-2-[(2S)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]propanamido]acetamido}-3-(1H-indol-3-yl)propanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 10909103
TTD Drug ID: DMUXMVQ

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cholecystokinin receptor type A (CCKAR)	TTCG0AL	CCKAR_HUMAN	Inhibitor	[1]
Gastrin/cholecystokinin type B receptor (CCKBR)	TTVFO0U	GASR_HUMAN	Inhibitor	[1]
Opioid receptor delta (OPRD1)	TT27RFC	OPRD_HUMAN	Inhibitor	[1]
Opioid receptor mu (MOP)	TTKWM86	OPRM_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Gastrin/cholecystokinin type B receptor (CCKBR)	DTT	CCKBR	5.618	5.638	5.466	6.002
Opioid receptor mu (MOP)	DTT	OPRM1	4.548	5.062	4.652	4.776
Cholecystokinin receptor type A (CCKAR)	DTT	CCKAR	3.907	4.133	2.858	3.892
Opioid receptor delta (OPRD1)	DTT	OPRD1	2.848	2.263	1.536	2

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Discovery agent

ICD Disease Classification

N.A.

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Opioid receptor mu (MOP)	DTT	OPRM1	5.94E-01	-0.02	-0.17
Opioid receptor delta (OPRD1)	DTT	OPRD1	5.52E-01	0.03	0.23

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.